Tempus AI's FDA Win Could Unlock Major Reimbursement Growth Ahead

Tempus AI received FDA approval for its tumor-only xT companion diagnostic, enabling a clearer path to higher pricing and potentially adding $85 million in annual revenues starting 2027, while awaiting further approvals and payer coverage.

This Wire brief sits within Fusion42's coverage of Healthtech Infrastructure.